Bronpass Tab.
Phase 2Small molecule
Bronpass Tab. is one of 40 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
120 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1EXDENSUR
GGlaxo Dba Glaxosmithkline
Phase 3
Lunsekimig
SanofiPhase 3
Tozorakimab
AstraZenecaPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Astegolimab
RochePhase 3
Titrated Oxygen
RRigshospitalet, Denmark
Phase 3
HSK39004
Haisco Pharmaceutical Group Co., Ltd.Phase 2
Calciferol
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Morphine Hydrochloride
Luye Pharma Group Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bronpass Tab.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHanlim Pharm. Co., Ltd.